Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 9/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13683784 | 1.00 | SPHK1 (0.43) | SPHK1L3MBTL1POLBCHRM3SPHK2 | |
| SCHEMBL14530162 | 1.00 | SPHK1 (0.43) | SPHK1L3MBTL1POLBCHRM3SPHK2 | |
| SCHEMBL13981439 | 0.94 | KMT2A (0.43) | SPHK1L3MBTL1POLBCHRM3SPHK2 | |
| SCHEMBL27282864 | 0.94 | KMT2A (0.43) | SPHK1L3MBTL1POLBCHRM3SPHK2 | |
| SCHEMBL27284632 | 0.94 | KMT2A (0.43) | SPHK1L3MBTL1POLBCHRM3SPHK2 | |
| SCHEMBL16941140 | 0.88 | GBA1 (0.39) | SPHK1L3MBTL1POLBCHRM3KMT2A | |
| SCHEMBL21870608 | 0.82 | CHRM3 (0.38) | L3MBTL1CHRM3KDM4EHTT | |
| SCHEMBL7024922 | 0.82 | CHRM3 (0.38) | L3MBTL1CHRM3KDM4EHTT | |
| SCHEMBL10808055 | 0.82 | CHRM3 (0.38) | L3MBTL1CHRM3KDM4EHTT | |
| SCHEMBL13839006 | 0.82 | TSHR (0.40) | L3MBTL1CHRM3KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| EP-2804861-B1 | SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | GENOSCO (US) | 2018-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | SPHK1 2180/4885L3MBTL1 1974/4885POLB 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.